Table_1.PDF
Kirsten Geneugelijk
Matthias Niemann
Julia Drylewicz
Arjan D. van Zuilen
Irma Joosten
Wil A. Allebes
Arnold van der Meer
Luuk B. Hilbrands
Marije C. Baas
C. Erik Hack
Franka E. van Reekum
Marianne C. Verhaar
Elena G. Kamburova
Michiel L. Bots
Marc A. J. Seelen
Jan Stephan Sanders
Bouke G. Hepkema
Annechien J. Lambeck
Laura B. Bungener
Caroline Roozendaal
Marcel G. J. Tilanus
Joris Vanderlocht
Christien E. Voorter
Lotte Wieten
Elly M. van Duijnhoven
Mariëlle Gelens
Maarten H. L. Christiaans
Frans J. van Ittersum
Azam Nurmohamed
Junior N. M. Lardy
Wendy Swelsen
Karlijn A. van der Pant
Neelke C. van der Weerd
Ineke J. M. ten Berge
Fréderike J. Bemelman
Andries Hoitsma
Paul J. M. van der Boog
Johan W. de Fijter
Michiel G. H. Betjes
Sebastiaan Heidt
Dave L. Roelen
Frans H. Claas
Henny G. Otten
Eric Spierings
10.3389/fimmu.2018.00321.s001
https://frontiersin.figshare.com/articles/dataset/Table_1_PDF/5947114
<p>Individual HLA mismatches may differentially impact graft survival after kidney transplantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor–recipient couples that were transplanted between 1995 and 2005. For these donors–recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04–1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for ln(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10–1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.</p>
2018-03-05 04:10:21
PIRCHE-II
kidney transplantation
graft rejection
HLA antigens
HLA matching